Literature DB >> 24076584

Current status of interleukin-10 and regulatory T-cells in cancer.

Kristen L Dennis1, Nichole R Blatner, Fotini Gounari, Khashayarsha Khazaie.   

Abstract

PURPOSE OF REVIEW: Tumor growth elicits antigen-specific cytotoxic as well as immune suppressive responses. Interleukin-10 (IL-10) is a key immune-suppressive cytokine produced by regulatory T-cells and by helper T-cells. Here, we review pleiotropic functions of IL-10 that impact the immune pathology of cancer. RECENT
FINDINGS: The role of IL-10 in cancer has become less certain with the knowledge of its immune stimulatory functions. IL-10 is needed for T-helper cell functions, T-cell immune surveillance, and suppression of cancer-associated inflammation. By promoting tumor-specific immune surveillance and hindering pathogenic inflammation, IL-10 is emerging as a key cytokine in the battle of the host against cancer.
SUMMARY: IL-10 functions at the cross-roads of immune stimulation and immune suppression in cancer. Immunological mechanisms of action of IL-10 can be ultimately exploited to develop novel and effective cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24076584      PMCID: PMC4322764          DOI: 10.1097/CCO.0000000000000006

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  185 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo.

Authors:  Abdelilah Wakkach; Nathalie Fournier; Valérie Brun; Jean-Philippe Breittmayer; Françoise Cottrez; Hervé Groux
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

Review 3.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

4.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen.

Authors:  O Akbari; R H DeKruyff; D T Umetsu
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

5.  CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.

Authors:  Susan E Erdman; Jane J Sohn; Varada P Rao; Prashant R Nambiar; Zhongming Ge; James G Fox; David B Schauer
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

6.  IL-10 suppresses CD2-mediated T cell activation via SHP-1.

Authors:  Alison Taylor; Johan Verhagen; Tunç Akkoç; Renate Wenig; Egbert Flory; Kurt Blaser; Mübeccel Akdis; Cezmi A Akdis
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

7.  Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering.

Authors:  Alexander D Edwards; Shivanthi P Manickasingham; Roman Spörri; Sandra S Diebold; Oliver Schulz; Alan Sher; Tsuneyasu Kaisho; Shizuo Akira; Caetano Reis e Sousa
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

8.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.

Authors:  H Groux; M Bigler; J E de Vries; M G Roncarolo
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

9.  Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.

Authors:  Alain P Vicari; Claudia Chiodoni; Céline Vaure; Smina Aït-Yahia; Christophe Dercamp; Fabien Matsos; Olivier Reynard; Catherine Taverne; Philippe Merle; Mario P Colombo; Anne O'Garra; Giorgio Trinchieri; Christophe Caux
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

10.  Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth.

Authors:  Elias Gounaris; Ching H Tung; Clifford Restaino; René Maehr; Rainer Kohler; Johanna A Joyce; Hidde L Ploegh; Hidde L Plough; Terrence A Barrett; Ralph Weissleder; Khashayarsha Khazaie
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  99 in total

1.  Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.

Authors:  Janis M Taube; Geoffrey D Young; Tracee L McMiller; Shuming Chen; January T Salas; Theresa S Pritchard; Haiying Xu; Alan K Meeker; Jinshui Fan; Chris Cheadle; Alan E Berger; Drew M Pardoll; Suzanne L Topalian
Journal:  Clin Cancer Res       Date:  2015-05-05       Impact factor: 12.531

2.  T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine.

Authors:  Kristen L Dennis; Abdulrahman Saadalla; Nichole R Blatner; Shuya Wang; Vysak Venkateswaran; Fotini Gounari; Hilde Cheroutre; Casey T Weaver; Axel Roers; Nejat K Egilmez; Khashayarsha Khazaie
Journal:  Cancer Immunol Res       Date:  2015-04-08       Impact factor: 11.151

Review 3.  FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Ther Targets       Date:  2018-04-10       Impact factor: 6.902

Review 4.  The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues.

Authors:  K Sanjana P Devi; Niroshana Anandasabapathy
Journal:  Semin Immunopathol       Date:  2016-11-25       Impact factor: 9.623

5.  Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer.

Authors:  Michael Doulberis; Katerina Angelopoulou; Eleni Kaldrymidou; Anastasia Tsingotjidou; Zaphiris Abas; Suzan E Erdman; Theofilos Poutahidis
Journal:  Carcinogenesis       Date:  2014-12-30       Impact factor: 4.944

6.  Foxp3 expression in CD4+CD25+Foxp3+ regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity.

Authors:  Xiao-Wen Zhu; Hai-Zhen Zhu; You-Qing Zhu; Mao-Hui Feng; Jian Qi; Zhi-Fen Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 7.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

8.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Chirag Acharya; Gang An; Michele Moschetta; Mike Y Zhong; Xiaoyan Feng; Michele Cea; Antonia Cagnetta; Kenneth Wen; Hans van Eenennaam; Andrea van Elsas; Lugui Qiu; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

9.  Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity.

Authors:  Luke S Manlove; Jason M Schenkel; Kezia R Manlove; Kristen E Pauken; Richard T Williams; Vaiva Vezys; Michael A Farrar
Journal:  J Immunol       Date:  2016-04-25       Impact factor: 5.422

Review 10.  Immunostimulatory biomaterials to boost tumor immunogenicity.

Authors:  Oluwaseyi T Shofolawe-Bakare; Larry D Stokes; Mehjabeen Hossain; Adam E Smith; Thomas A Werfel
Journal:  Biomater Sci       Date:  2020-09-02       Impact factor: 6.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.